AI Summary
The analysis by the US CDC showed that improvements in routine coverage of the HPV vaccine in the USA have stalled since the COVID-19 pandemic. The study looked at data from 2023, which revealed that only 61.4% of adolescents aged 13-17 were up to date with the full HPV vaccine schedule, a slight decrease from the previous year. This suggests that suboptimal vaccine coverage continues to be a concern in the USA.
A new analysis by the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) has revealed that improvements in routine coverage of the human papillomavirus (HPV) vaccine in the USA have stalled since the COVID-19 pandemic. Investigators from CDC examined national survey data from 2023, drawn from 16 658 adolescents aged 13–17 years, who were born between 2005 and 2010. 61·4% (95% CI 59·9–63·0) of these individuals were up to date with the full schedule of the HPV vaccine in 2023, compared with 62·6% (95% CI 61·1–64·0) in 2022.